Quinhub 400 Tablet contains Hydroxychloroquine 400mg, a widely prescribed antimalarial and immunomodulatory agent. It is commonly used for the prevention and treatment of malaria, as well as for managing autoimmune disorders like rheumatoid arthritis and systemic lupus erythematosus. Its dual mechanism helps in inhibiting parasite growth and modulating immune system activity, providing both therapeutic and preventive benefits.
The formulation ensures consistent efficacy and patient compliance, making it suitable for long-term therapy in autoimmune conditions and periodic malaria prevention. Hydroxychloroquine 400mg is effective in reducing inflammation, pain, and immune-mediated tissue damage while maintaining safety when used under proper medical supervision.
Belonging to the anti-infective and immunomodulatory segment, Quinhub 400 Tablet is in high demand among hospitals, specialty clinics, and PCD pharma franchise networks. Its well-established clinical profile, ease of administration, and wide application make it a preferred choice for healthcare providers.
For PCD franchise partners, Quinhub 400 Tablet represents a high-margin, high-demand opportunity. Its strong market presence in both malaria prophylaxis and autoimmune therapy, along with B2B distribution potential, ensures consistent growth and profitability across domestic and export pharma segments.